Unlicensed herbal medicine (UAM) is often used to treat symptoms of a number of conditions, including back pain, arthritis, rheumatoid arthritis, and other conditions.
The US Food and Drug Administration (FDA) has approved UAM as an alternative to traditional drugs such as steroids and antibiotics, but it has also been criticized for potentially causing side effects, including increased heart rate, breathing difficulties, and decreased blood pressure.
According to research by researchers at UC Berkeley, the FDA’s approval of UAM may have been influenced by concerns about side effects and the potential for abuse.
In a paper published in the journal Drug and Alcohol Dependence, the researchers describe how the FDA rejected UAM for several reasons, including concerns about safety.
They also found that the FDA did not consider the potential harms of Uam to the public, which is important because it may make it more difficult for physicians to use UAM.
“The fact that the agency did not give it an opportunity to demonstrate that its safety was likely to outweigh the potential risks is problematic,” said the researchers.
UAM is marketed by a variety of companies, including the pharmaceutical giant Pfizer.
The FDA approved UMA in 2006, but the approval expired in 2016.
As the FDA reviews the scientific evidence to approve UAM, the agency has also given a few more reasons for not approving the drug, including safety concerns, the possibility of diversion of the drug to other products, and concerns about its use.
According a spokesperson for the FDA, UAM does not meet the criteria for a Schedule I drug.
However, the company did not respond to a request for comment from Newsweek.